The high-stakes trade-off of modern Alzheimer’s treatments

Science · Published 7 October 2026 Swipe more like this →

In short: New FDA-approved drugs aim to stop Alzheimer's at its biological source by clearing brain plaques. However, these therapies aren't simple cures; they involve a complex gamble between marginal gains in cognitive independence and the risk of severe, sometimes fatal, neurological side effects.

In 2021, the FDA approved treatments designed to remove amyloid plaques, which have long been identified as a primary driver of Alzheimer's symptoms. These monoclonal antibodies, such as lecanemab and donanemab, represent a shift toward disease-modifying therapies rather than just symptom management. While they are the first drugs shown to potentially change the course of this deadly disease, their clinical impact remains a subject of intense debate among neurologists.

The data suggests the benefits may be modest. Clinical trials indicate that these drugs can slow cognitive decline by approximately 25% to 30% over an 18-month period. For some patients, this might translate to roughly one additional year of functional independence. However, critics point out that the success of these treatments is tempered by significant risks. A high percentage of participants in studies experienced amyloid-related imaging abnormalities (ARIA), which include brain swelling and microbleeds.

The safety profile is concerning: up to 40 percent of patients showed brain swelling, while up to 28 percent experienced brain bleeds. These complications can lead to disability or death, particularly for those carrying the APOE4 gene or taking anticoagulants. This has created a prescribing dilemma; some physicians view the benefits as 'minuscule' compared to the risks, while others believe that even a small delay in progression is a compelling reason to offer the treatment to early-stage patients.

This stands in contrast to older medications like Cholinesterase Inhibitors (e.g., Donepezil), which are primarily used to manage symptoms by increasing acetylcholine levels. While those drugs show slight improvements or stabilization for 50-60% of people over six months, they do not target the underlying pathology. The new anti-amyloid therapies represent a frontier where the goal is to alter the disease itself, but the path forward remains clouded by uncertainty regarding long-term efficacy and real-world safety.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• Guidelines for using lecanemab focus on matching clinical practice to trial conditions
• Alzheimer's drug trials have failed 99.5% of the time
• Why targeting a single protein hasn't cured Alzheimer’s disease
• Alzheimer’s still has no treatment that reverses it
• Brain imaging abnormalities were frequently observed during aducanumab clinical trials
• The elegant logic behind solving second-order differential equations
• A microscopic parasite that can travel from your gut to your brain
• Is there a scientifically backed antidote to the persistent feeling of dissatisfaction?
• How one creator funds his children's education through the power of educational video production.
• If black holes destroy information, our universe loses its memory
• The Amazon pumps 7 trillion tons of water into the atmosphere annually
• Why television crime dramas often misrepresent the reality of forensic science

More in Science · Latest · A–Z · All topics